Register for our free email digests:
Division of Pfizer Inc.
Latest From Checkmate Pharmaceuticals Inc.
June venture capital financings for emerging companies totaled more than $688.8m, ranging from an undisclosed round for Avitide to a $120m Series B for Rubius Therapeutics.
Athenex and Immuron launched IPOs in the US, but June has otherwise been a pretty quiet month for new biopharma financings – so far. The largest VC round so far this month is Checkmate's $27m Series B and the biggest public offering was conducted by CTI BioPharma, raising $45m.
Recent executive-level hires and director appointments at venture capital firms and biopharma and medtech start-ups.
Recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Pfizer Inc.
- Senior Management
Lawrence E Tilton, Pres. & CEO
Robert Dougan, VP, Medical Licensing & Acquisitions
Mark Perrin, VP & GM, Pharmaceuticals
Hank Meyer, MD, Pres., Medical Research Div.
- Contact Info
Phone: (845) 732-5000
North Middletown Rd.
Pearl River, NY 10965
You must sign in to use this functionality
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.